Plain-English translation of NCT07449754 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a new medication, works better when combined with another drug called cobimetinib to treat advanced melanoma (a type of skin cancer) that has a specific genetic mutation called NRAS. The study will measure how many people respond to the treatment, how long the response lasts, and what side effects occur.
Many people with advanced melanoma that has an NRAS mutation don't respond well to standard treatments, or their cancer comes back after treatment. This study is exploring whether this medication combination could offer a new, more effective option for these patients.
You likely qualify if…
You likely don't qualify if…
You would take both medications by mouth together in 28-day cycles for as long as they are helping you and you can tolerate them. You'll have regular clinic visits to check how the cancer is responding, monitor your blood work and organ function, and watch for any side effects. The study involves visits at a cancer research center where doctors will measure your tumors with imaging scans periodically to see if the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
South Korea